Myocardial infarction

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
4 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody 1 substance
Unknown / small molecule 1 substance
Supportive / diluent 1 substance
Phase II: 1 Phase IV: 2 Other: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

1 trial
  • Abcentra LLC Commercial
    ORTICUMAB
    2025-520464-17-00 7 countries 2025 n=184
    Recruiting

Phase IV

2 trials
  • Klinikum der Universitaet Muenchen AöR Academic
    IMP not specified
    2024-512727-36-00 2 countries 2021 n=1,474
    Ended
  • Wroclaw Medical University Academic
    FERRIC CARBOXYMALTOSE; SODIUM CHLORIDE
    2024-517206-28-00 1 country 2022 n=1,000
    Recruiting

Other

1 trial
  • Celon Pharma S.A. Commercial
    IMP not specified
    2023-504116-14-00 1 country 2023 n=40
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celon Pharma S.A. Commercial 1 Other 0
Abcentra LLC Commercial 1 Phase II 1
Klinikum der Universitaet Muenchen AöR Academic 1 Phase IV 0
Wroclaw Medical University Academic 1 Phase IV 1
New trials by year
2021
1
2022
1
2023
1
2025
1
← All indication landscapes